Ownership history in Birchview Capital, LP Β· 9 quarters on record
This page tracks every 13F SEC filing in which Birchview Capital, LP reported a position in CASTLE BIOSCIENCES INC (CSTL). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Birchview Capital, LP outperformed the S&P 500 by +29.9% annually on this CSTL position. Timing score: 50% (3/6 decisions correct). Average cost basis: $23.89. Maximum drawdown during holding period: β29.8%.
π₯ Exceptional β beat the S&P 500 by 29.9% per year on this position.
7 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
3 of 6 add/trim decisions correct
Best entry: $20.02 (2025 Q1) Β· Worst: $28.52 (2024 Q3)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
7 adds Β· 1 trim. Bought during 3 of 3 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π Birchview Capital, LP has been actively increasing its CSTL allocation β a bullish signal from insiders.
Currently 1.84% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size